Skip to main content
. Author manuscript; available in PMC: 2019 Jan 18.
Published in final edited form as: ACS Appl Mater Interfaces. 2018 May 15;10(21):17792–17808. doi: 10.1021/acsami.8b05607

Figure 7.

Figure 7.

Comparative delivery of doxorubicin into HT-29 tumor spheroids by THZN, NTHZN nanoplatforms versus free doxorubicin (at identical initial drug dose of 5 µg/mL), revealed via a) confocal fluorescence microscopy, showing spheroid image and fluorescence signal in cross section and b) quantified by fluorescence spectroscopy, post spheroid digestion.